Monographie - Infliximab - Stabilis 4.0

Siste oppdatering :
19/11/2024

Immunosuppressiva

Infliximab

Injeksjon

Øyedråper

Oppløsningsstabilitet

Stabilitet i blandinger

Faktorer som påvirker stabiliteten

Kompatibilitet

Administrasjonsmåte

Referanser

pdf

Handelsnavn

Handelsnavn

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Flixabi	Belgia, Spania, Storbritannia, Tyskland
Flixceli	Peru
Inflectra	Belgia, Canada, Island, Italia, Romania, Spania, Storbritannia, Sveits, Tyskland
Infliximab	Chile
Remicade	Argentina, Australia, Belgia, Canada, Chile, Colombia, Danmark, De forente arabiske emirater, Ecuador, Finland, Frankrike, Hellas, Iran, Irland, Island, Italia, Japan, Luxembourg, Malaysia, Mexico, Nederland, New Zealand, Norge, Peru, Polen, Portugal, Romania, Saudi-Arabia, Spania, Storbritannia, Sveits, Sverige, Tunisia, Tyrkia, Tyskland, USA, Venezuela, Østerrike
Remsima	Argentina, Belgia, Canada, Chile, Ecuador, Frankrike, Island, Italia, Norge, Peru, Romania, Spania, Storbritannia, Sveits, Tyrkia, Tyskland
Zessli	Belgia, Storbritannia, Tyskland

Referanser

Injeksjon

Referanser : Infliximab

	Type	publikasjon
754	Labratorium	Infliximab (Remicade®) – Summary of Product Characteristics Merck Sharp & Dohme 2019
2296	Labratorium	Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017
3137	Journal	Beer PM, Wong SJ, Schartman JP, Kulas KE, Hartman CL, Giganti M, Falk NS. Infliximab stability after reconstitution, dilution, and storage under refrigeration. Retina 2010 ; 30, 1: 81-84.
3317	plakat	Guirao S, Paul M, Jaccoulet E, Morand K, Astier A. Stabilité de l'infliximab en solutions diluées. APHIF Congress 2009
3333	Journal	Ikeda R, Vermeulen L.C, Lau E, Jiang Z, Saha S, Reichelderfer M, Kolesar J.M. Stability of infliximab in polyvinyl chloride bags. Am J Health-Syst Pharm 2012 ; 69:1509-1512.
3825	Journal	Young B.L, Ali Khan M, Chapman T.J, Parry R,. Connolly M.A, Watts A.G. Evaluation of the physicochemical and functional stability of diluted REMSIMA(R) upon extended storage—A study compliant with NHS (UK) guidance. J Pharm Pract and Res 2015 ; 496: 421-431.
3924	Journal	Vieillard V, Astier A, Sauzay C, Paul M. One-month stability study of a biosimilar of infliximab (Remsima®) after dilution and storage at 4 C and 25 C. Ann Pharm Fr 2016 ; 75, 1 : 17-29.
4003	Journal	Kim J, Chung J, Park S, Jung S, Kang D. Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab). EJHP 2017 ; 25, 3: 157-164.
4049	Journal	Tokhadze N, Chennell P, Le Basle Y, Sautou V. Stability of infliximab solutions in different temperature and dilution conditions. J Pharm Biomed Anal 2018 ; 150 : 386-395
4279	Journal	Hermosilla J, Sanchez-Martin R, Pérez-Robles R, Salmeron-Garcia A, Casares S, Cabeza J, Cuadros-Rodriguez L, Navas N. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA). Bio Drugs 2019 ; 33: 193–205.
4292	Journal	Vimpolsek M, Gottar-Guillier M, Rossy E. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion. Drugs R D 2019 19: 127–140.

Mentions Légales